Indoco Remedies Ltd

About Indoco Remedies Ltd

Indoco Remedies Ltd. is an Indian pharmaceutical company engaged in the manufacturing and marketing of finished dosages and active pharmaceutical ingredients (APIs). It focuses on therapeutic areas like ophthalmic, dental, pain management, and respiratory. The company has a significant presence in both domestic and international markets, including regulated markets.

Key Financial Ratios of Indoco Remedies Ltd

• P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Indoco Remedies Ltd's P/E ratio (TTM) is -399.74, compared to the industry median of 22.51 and large cap median of 22.45.

• P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Indoco Remedies Ltd's P/B ratio is 2.39, compared to the industry median of 1.72 and large cap median of 1.71.

• P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Indoco Remedies Ltd's P/S ratio is 1.22, compared to the industry median of 0.90 and large cap median of 0.88.

• PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Indoco Remedies Ltd's PEG ratio is 1.50.

• EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Indoco Remedies Ltd's EV/EBITDA ratio is 19.77.

• Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Indoco Remedies Ltd's ROE is -10.54%.

• Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Indoco Remedies Ltd's ROA is 5.48%.

• Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Indoco Remedies Ltd's ROCE is 1%.

• Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Indoco Remedies Ltd's operating margin is 7.70%.

• Net Margin: Net margin shows what percentage of revenue converts into final net profit. Indoco Remedies Ltd's net margin is -5.37%.

• Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Indoco Remedies Ltd's current ratio is 1.21.

• Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Indoco Remedies Ltd's debt-to-equity ratio is 0.61.

• Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Indoco Remedies Ltd's interest coverage ratio is 0.12.

• Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Indoco Remedies Ltd's DPS is ₹0.21.

• Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Indoco Remedies Ltd's EPS is -29.04.

(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹243.84. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")

Key Facts

• Founded: 1947

• Headquarters: Mumbai, Maharashtra

• Core Offerings: Finished dosages, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), Pharmaceutical exports, Domestic formulations

• Stock Listing: NSE (INDOCO), BSE (532612)

• Promoter: Suresh G. Kare / Indoco Remedies Promoter Group

History of Indoco Remedies Ltd

• 1947: Founded by Mr. N. B. Kare in Mumbai.

• 1951: Commenced manufacturing operations at its first plant in Mumbai.

• 1975: Established its research and development centre.

• 1990s: Expanded manufacturing capabilities and entered international markets.

• 2000s: Focused on building a robust product pipeline and scaling up exports, especially to regulated markets like the US and Europe.

• 2007: Launched ophthalmic manufacturing facility.

• Present Day: Operates multiple manufacturing facilities, a dedicated R&D center, and markets a wide range of formulations globally.

Business Segments and Revenue Mix

• Domestic Formulations: Focuses on marketing and sales of a diverse portfolio of prescription drugs across various therapeutic areas such as ophthalmic, dental, anti-infectives, pain management, respiratory, gastro-intestinal, and vitamins. It has a strong field force and distribution network across India.

• International Formulations (Exports): Exports finished dosage forms to over 55 countries, including highly regulated markets like the USA and Europe, as well as emerging markets. The company has a robust pipeline of ANDAs and dossiers for these markets.

• APIs & CRAMS: Manufactures Active Pharmaceutical Ingredients primarily for captive consumption and also for sales to other pharmaceutical companies. Offers Contract Research and Manufacturing Services (CRAMS) for both intermediates and APIs.

Key Personnel

Suresh G. Kare: Chairman & Managing Director. Veteran in the pharmaceutical industry with over five decades of experience, playing a pivotal role in Indoco's growth and strategic direction. Aditi Panandikar: Managing Director. Leads operations and strategy, with extensive experience in pharmaceutical manufacturing and regulatory affairs.

Subsidiaries and Associate Companies

• Indoco Remedies Inc. (USA)

• Indoco Pharmaceuticals Limited (UK)

Corporate Actions

Bonus Issue: 1:2 in June 2023. No other major recent corporate actions on record.

References

1. Annual Report FY24 2. Exchange Filings (NSE/BSE) 3. Financial Results Announcement